Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs)

被引：0
|
作者：
Almeida, Antonio [1 ]
Santini, Valeria [2 ]
Croepper, Stefanie [3 ]
Jonasova, Anna [4 ]
Vey, Norbert [5 ]
Giagounidis, Aristoteles [3 ]
Hellstrom-Lindberg, Eva [6 ]
Mufti, Ghulam J. [7 ]
Sanz, Guillermo [8 ]
Skikne, Barry [9 ]
Hoenekopp, Albert [10 ]
Seguy, Francis [10 ]
Zhong, Jianhua [9 ]
Fenaux, Pierre [11 ]
机构：
[1] Inst Portugues Oncol Francisco Gentil, Lisbon, Portugal
[2] Univ Florence, AOU Careggi, Florence, Italy
[3] Marien Hosp, Dusseldorf, Germany
[4] Charles Univ Prague, Gen Hosp, Dept Med 1, Prague, Czech Republic
[5] Ctr Reg Lutte Canc, Inst Paoli Calmettes, Marseille, France
[6] Karolinska Univ Hosp, Stockholm, Sweden
[7] Kings Coll Hosp London, London, England
[8] Hosp Univ Politecn La Fe, Valencia, Spain
[9] Celgene Corp, Summit, NJ USA
[10] Celgene Int, Boudry, Switzerland
[11] Univ Paris 07, Hop St Louis, Serv Hematol Seniors, Paris, France
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
10.1182/blood.V126.23.2880.2880
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] TREATMENT OF LOWER RISK MDS WITH DEL 5Q WITH LENALIDOMIDE (LEN): CURRENT RESULTS OF THE FRENCH PATIENT NAMED PROGRAM (ATU)
    Le Bras, E.
    Sebert, M.
    Eclache, V.
    Lamy, T.
    Dlaunay, J.
    Visanica, S.
    Dreyfus, E.
    Banos, A.
    Blanc, M.
    Leyronnas, C.
    Besson, C.
    Derenzis, B.
    Thomas, X.
    Rodon, C.
    Vey, N.
    Gardernbas, M.
    Faron, M.
    Bauduer, F.
    Ramee, J. E.
    Zajec, D.
    Delmer, A.
    Rea, D.
    Beyne-Rauzy, O.
    Ceccaldi, J.
    Beaucournou, P.
    Dugay, J.
    Fenaux, P.
    Ades, L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 96 - 96
  • [22] Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe
    Diez-Campelo, Maria
    Yucel, Aylin
    Goyal, Ravi K.
    Parikh, Rohan C.
    Esterberg, Elizabeth
    Jimenez, Maria
    Sluga-O'Callaghan, Martina
    Miteva, Dimana
    Xiao, Hong
    Germing, Ulrich
    FUTURE ONCOLOGY, 2024,
  • [23] DEFINING LIKELIHOOD OF FUTURE RESPONSE IN PATIENTS WITH DEL(5Q) MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH LENALIDOMIDE
    Gerds, A. T.
    List, A. F.
    Giagounidis, A.
    Hellstrom-Lindberg, E.
    Li, J. Shiansong
    Swern, A. S.
    Sugrue, M. M.
    Fenaux, P.
    Sekeres, M. A.
    LEUKEMIA RESEARCH, 2015, 39 : S109 - S109
  • [24] LENALIDOMIDE (LEN) IN MYELODYSPLASTIC (MDS) DEL(5Q) PATIENTS: A SINGLE INSTITUTION POPULATION-BASED EXPERIENCE
    Pelizzari, A.
    Cerqui, E.
    Schieppati, F.
    Borlenghi, E.
    Pagani, C.
    Bellotti, D.
    Rossi, G.
    HAEMATOLOGICA, 2013, 98 : 580 - 580
  • [25] Treatment of myelodysplastic syndromes with del 5q before the lenalidomide era:: The GFM experience.
    Kelaidi, Charikleia
    Park, Sophie
    Brechignac, Sabine
    Mannone, Lionel
    Vey, Norbert
    Dombret, Herve
    Aljassem, Lina
    Starnatoullas, Aspasia
    Ades, Lionel
    Giraudier, Setphane
    de Botton, Stephane
    Mahe, Beatrice
    Lepelley, Pascale
    Picard, Fracoise
    Leroux, Genevieve
    Daniel, Marie-Threrese
    Bouscary, Didier
    Dreyfus, Francois
    Fenaux, Pierre
    BLOOD, 2006, 108 (11) : 757A - 757A
  • [26] Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomide
    Beier, Fabian
    Kharabi Masouleh, Behzad
    Buesche, Guntram
    Ventura Ferreira, Monica S.
    Schneider, Rebekka K.
    Ziegler, Patrick
    Wilop, Stefan
    Vankann, Lucia
    Gattermann, Norbert
    Platzbecker, Uwe
    Giagounidis, Aristoteles
    Goetze, Katharina S.
    Nolte, Florian
    Hofmann, Wolf-Karsten
    Haase, Detlef
    Kreipe, Hans
    Panse, Jens
    Blasco, Maria A.
    Germing, Ulrich
    Bruemmendorf, Tim H.
    LEUKEMIA RESEARCH, 2015, 39 (11) : 1292 - 1298
  • [27] Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
    Mostafa Abdallah
    Kaaren Reichard
    Naseema Gangat
    Ayalew Tefferi
    Blood Cancer Journal, 14
  • [28] TREATMENT-EMERGENT ADVERSE EVENTS IN LENALIDOMIDE-TREATED LOW/INT-1-RISK MYELODYSPLASTIC SYNDROMES PATIENTS WITHOUT DEL(5Q) INELIGIBLE FOR OR REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS
    Almeida, A.
    Fenaux, P.
    Garcia-Manero, G.
    Giagounidis, A.
    Goldberg, S.
    Groepper, S.
    Jonasova, A.
    Mufti, G. J.
    Sanz, G. F.
    Vey, N.
    Castaneda, C.
    Zhong, J.
    Beach, C.
    Santini, V.
    HAEMATOLOGICA, 2016, 101 : 502 - 502
  • [29] Treatment-emergent mutations in myelodysplastic syndrome with del(5q) - lenalidomide related or disease-intrinsic clonal evolution?
    Abdallah, Mostafa
    Reichard, Kaaren
    Gangat, Naseema
    Tefferi, Ayalew
    BLOOD CANCER JOURNAL, 2024, 14 (01)
  • [30] ECONOMIC EVALUATION OF LENALIDOMIDE IN THE TREATMENT OF LOWER RISK MYELODYSPLASTIC SYNDROMES WITH DEL5Q (MDS DEL5Q) IN MEXICO
    Ramos, C.
    Montano, E.
    Reyes Lopez, A.
    Pacheco-Alvarez, I
    Hernandez-Rivera, G.
    Lemus-Carmona, E. A.
    VALUE IN HEALTH, 2016, 19 (03) : A248 - A248
12345